This trial is active, not recruiting.

Conditions aortic stenosis, aortic sclerosis
Sponsor Charles University, Czech Republic
Start date January 2005
End date December 2008
Trial size 300 participants
Trial identifier NCT00375336, IGA MH NR/8306-5


The purpose of this study is

- to determine the degree of endothelial dysfunction and inflammation in calcific aortic valve disease associated with coronary artery disease(CAD).

- to determine whether there is relationship between calcium metabolism and calcific aortic valve disease associated with CAD.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Patients with aortic stenosis (mean transvalvular aortic gradient ≥30 mm Hg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
Patients with nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
Patients with normal aortic valve plus angiographically significant coronary artery disease (more than 50% diameter stenosis)

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion criteria: - significant stenosis (more than 50% diameter stenosis) of one or more coronary arteries - aortic sclerosis (group 1) or stenosis (AVA < 1cm2/m2, or mean gradient ≥ 30 mmHg) (group 2) or normal aortic valve (group 3) Exclusion criteria: - Rheumatic heart disease (defined as aortic stenosis with commissural fusion + rheumatic mitral valve disease) - Status post aortic valve replacement - Congenital complex heart disease (except bicuspid aortic valve) - Moderate to severe aortic insufficiency (grade > 2/4) - Marfan syndrome - Infective endocarditis - Hypertrophic obstruction cardiomyopathy - Acute coronary syndrome within less than three months - Severe heart failure, NYHA class IV - Severe locomotion disability - Renal failure requiring dialysis - Significant systemic disease or other disease severely limiting the patient prognosis (e.g. known cancer, liver cirrhosis) - Primary hyperparathyroidism - Patient non-compliance

Additional Information

Official title Risk Markers of Coronary Artery Disease Associated With Calcific Aortic Valve Disease
Principal investigator Katerina Linhartova, MD, PhD
Description Cardiovascular disease, mainly coronary artery disease, causes more than one half of deaths in the developed countries. Only recently, calcific aortic valve disease, was proved to belong to the family of atherosclerosis. It is associated with higher cardiovascular morbidity and mortality, the cause of which is not entirely clear. The link to significant coronary artery disease, probably, is of highest importance. We compare groups of patients with coronary artery disease and calcific stenotic, sclerotic or intact aortic valve. The aim is to assess and compare their risk profile to verify our hypothesis that, within significant coronary artery disease, calcific aortic valve identifies a subgroup of patients with higher cardiovascular risk, assessed by endothelial dysfunction and the two year follow-up of cardiovascular events on optimally set treatment. Further, we study the possible association of valvular calcification and calcium metabolism in patients with normal kidney function.
Trial information was received from ClinicalTrials.gov and was last updated in December 2008.
Information provided to ClinicalTrials.gov by Charles University, Czech Republic.